Symbol | Exchange | Currency |
---|
Investing.com - Catalyst Pharmaceuticals (NASDAQ: CPRX) reported first quarter EPS of $0.310, $0.11 better than the analyst estimate of $0.200. Revenue for the quarter came in at...
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing...
Value and growth investing are two approaches to long-term investing. Both academic scholars and investment professionals discuss and debate the merits and risks associated with...
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) reported earnings of 7 cents per share in the fourth quarter of 2019, missing the Zacks Consensus Estimate of 9 cents. Meanwhile, the...
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) provided a corporate update, including preliminary net revenues, for 2019.The company’s only FDA-approved product...
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Average | 21.650 (+31.531% Upside) |
High | 25.000 |
Low | 16.250 |
Price | 16.460 |
No. of Analysts | 5 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
---|---|---|---|---|---|
Moving Averages | Sell | Buy | Buy | Buy | Buy |
Technical Indicators | Buy | Strong Buy | Strong Sell | Strong Buy | Strong Buy |
Summary | Neutral | Strong Buy | Neutral | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
---|---|---|---|---|---|---|---|---|---|
195.28 | 197.33 | 194.42 | +1.40 | +0.72% | 109.50M | NASDAQ | |||
162.36 | 162.47 | 161.27 | +1.59 | +0.99% | 46.76M | NASDAQ | |||
61.85 | 62.09 | 61.66 | -0.01 | -0.02% | 8.35M | NYSE | |||
207.84 | 208.09 | 202.82 | +2.49 | +1.21% | 22.53M | NASDAQ | |||
100.89 | 101.15 | 99.78 | -0.50 | -0.49% | 32.74M | NASDAQ | |||
284.05 | 284.46 | 281.48 | +3.54 | +1.26% | 24.97M | NASDAQ | |||
40.38 | 40.49 | 40.25 | +0.13 | +0.32% | 12.49M | NYSE | |||
97.88 | 99.53 | 97.25 | +1.79 | +1.86% | 58.34M | NASDAQ | |||
102.00 | 103.04 | 101.01 | +1.75 | +1.75% | 51.96M | NASDAQ | |||
162.67 | 164.50 | 162.41 | +0.54 | +0.33% | 1.16M | NASDAQ | |||
273.83 | 274.99 | 271.02 | +3.99 | +1.48% | 35.62M | NASDAQ | |||
8.15 | 8.38 | 8.05 | -0.07 | -0.85% | 20.57M | NYSE | |||
101.32 | 101.61 | 100.29 | -0.58 | -0.57% | 24.17M | NASDAQ | |||
46.51 | 47.32 | 46.02 | -0.19 | -0.41% | 12.10M | NYSE | |||
10.27 | 10.275 | 10.27 | -0.010 | -0.10% | 66.38K | NYSE |